European medical technology industry adopts revised code of ethical business practice
Posted on 28.03.2022
The Code of Ethical Business Practice is a self-regulatory instrument developed by the medical technology industry which regulates all aspects of the industry’s relationship with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs).
The 2022 revised Code reflects evolving standards and best business practices over the last couple of years – since MedTech Europe’s last Code update in 2015 – and is designed as the core document for ethics and compliance across the European medical technology industry.
“This revision, which also enhances usability and reader-friendliness, shows our industry’s continued commitment to ethics, integrity and transparency.”, said Serge Bernasconi, CEO of MedTech Europe.
The revisions will be effective as of 1 January 2023, to ensure ample time for implementation and transposition by member companies as well as National Associations. Key changes include, among other things: revisions to provide additional clarity, additional guidance on Collaborative Research, new definitions in the Glossary and an explanation of the existing Code provisions, as well as the consolidation and clarification of the existing rules around Distributor relations and Virtual Events.
“By clarifying existing provisions, adding new sections to address additional types of HCP interactions, and further developing the Code’s underlying values, the updates further support industry’s strong compliance principles.”, Bernasconi said.
“These updates continue to focus the industry on the necessary collaborations with physicians and other HCPs to bring the most effective and innovative care to patients in Europe and beyond,” added Rob ten Hoedt, Chairman of the MedTech Europe Board and EMEA President of Medtronic.
To access the updated Code – along with an overview document and additional information – please click here.
Additional Background
Compliance with existing laws is not enough to protect the integrity and reputation of the industry. Currently, anti-corruption laws vary substantially across countries, even within Europe. The Code aims to offer a level playing field for companies operating in different markets while ensuring the highest compliance standards. The Code was developed as the industry’s commitment to support clear and strict self-regulation to protect its reputation. The Code clarifies and distinguishes appropriate activities between HCPs, as well as HCOs, and MedTech Europe member companies. The Code has also served as the foundation for National Associations’ codes of ethics.